心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

2018 EHRA实践指导：房颤患者应用非维生素K拮抗剂口服抗凝药

2018-03-20 欧洲心律学会 European Heart Journal (2018) 00, 1–64

房颤口服抗凝剂非维生素K拮抗剂

2018年3月，欧洲心律学会(EHRA)发布了房颤患者应用非维生素K拮抗剂口服抗凝药实践指导，非维生素K拮抗剂口服抗凝药(NOACs)是卒中患者应用维生素K拮抗剂预防房颤的一个选择，尤其在刚开始接受抗凝治疗的患者中已经成为首选。EHRA第1版实践指导已经作为房颤指南的补充于2013年发布并于2015年进行第一次更新，本文作为2018更新版本，共提出了20个临床应用情景。

中文标题：

2018 EHRA实践指导：房颤患者应用非维生素K拮抗剂口服抗凝药

英文标题：

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

发布机构：

欧洲心律学会

发布日期：

2018-03-20

简要介绍：

2018年3月，欧洲心律学会(EHRA)发布了房颤患者应用非维生素K拮抗剂口服抗凝药实践指导，非维生素K拮抗剂口服抗凝药(NOACs)是卒中患者应用维生素K拮抗剂预防房颤的一个选择，尤其在刚开始接受抗凝治疗的患者中已经成为首选。EHRA第1版实践指导已经作为房颤指南的补充于2013年发布并于2015年进行第一次更新，本文作为2018更新版本，共提出了20个临床应用情景。

 

拓展指南：与房颤相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2018 EHRA实践指导：房颤患者应用非维生素K拮抗剂口服抗凝药)] GetToolGuiderByIdResponse(projectId=1, id=445b61c0015e2325, title=2018 EHRA实践指导：房颤患者应用非维生素K拮抗剂口服抗凝药, enTitle=The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation, guiderFrom=European Heart Journal (2018) 00, 1–64, authorId=null, author=, summary=2018年3月，欧洲心律学会(EHRA)发布了房颤患者应用非维生素K拮抗剂口服抗凝药实践指导，非维生素K拮抗剂口服抗凝药(NOACs)是卒中患者应用维生素K拮抗剂预防房颤的一个选择，尤其在刚开始接受抗凝治疗的患者中已经成为首选。EHRA第1版实践指导已经作为房颤指南的补充于2013年发布并于2015年进行第一次更新，本文作为2018更新版本，共提出了20个临床应用情景。 , cover=, journalId=null, articlesId=null, associationId=206, associationName=欧洲心律学会, associationIntro=欧洲心律学会（EHRAE,uropean Heart Rhythm Association)是欧洲心脏病学会的分支，致力于心律失常的预防与管理，以减少心律失常对患者的影响,减少心源性猝死。官方杂志《欧洲心律失常杂志》影响因子为1.839, copyright=0, guiderPublishedTime=Tue Mar 20 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<P>2018年3月，欧洲心律学会(EHRA)发布了房颤患者应用非维生素K拮抗剂口服抗凝药实践指导，非维生素K拮抗剂口服抗凝药(NOACs)是卒中患者应用维生素K拮抗剂预防房颤的一个选择，尤其在刚开始接受抗凝治疗的患者中已经成为首选。EHRA第1版实践指导已经作为房颤指南的补充于2013年发布并于2015年进行第一次更新，本文作为2018更新版本，共提出了20个临床应用情景。 </P> <P> </P>拓展指南：<strong>与<font color=red>房颤</font>相关指南：</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=239281c00151e6c5" title="2017 EHRA/ESC共识文件：心脏瓣膜病相关性房颤的抗栓治疗" target=_blank>2017 EHRA/ESC共识文件：心脏瓣膜病相关性房颤的抗栓治疗</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=04ad11c00151229a" title="2017 EHRA共识文件：心房颤动的筛查" target=_blank>2017 EHRA共识文件：心房颤动的筛查</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=f42101c001a48930" title="2016 SBC指南：心房颤动（执行纲要）" target=_blank>2016 SBC指南：心房颤动（执行纲要）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=df8f51c001a488db" title="2017 AAFP临床实践指南：新发现房颤的药物治疗（更新版）" target=_blank>2017 AAFP临床实践指南：新发现房颤的药物治疗（更新版）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=1253e1c001a38ea1" title="2016年欧洲心脏病学会心房颤动管理指南（节选）（二）" target=_blank>2016年欧洲心脏病学会心房颤动管理指南（节选）（二）</a></li> 更多信息请点击：<a href="http://www.medsci.cn/guideline/list.do?q=%E6%88%BF%E9%A2%A4" target=_blank>有关房颤更多指南</a></ul>, tagList=[TagDto(tagId=364, tagName=房颤), TagDto(tagId=2729, tagName=口服抗凝剂), TagDto(tagId=27960, tagName=非维生素K拮抗剂)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=0, guiderRegion=2, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=9597, appHits=521, showAppHits=0, pcHits=6925, showPcHits=3298, likes=141, shares=11, comments=6, approvalStatus=1, publishedTime=Tue Mar 27 21:23:22 CST 2018, publishedTimeString=2018-03-20, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Tue Mar 27 21:23:22 CST 2018, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 09:30:12 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 EHRA实践指导：房颤患者应用非维生素K拮抗剂口服抗凝药)])
2018 EHRA实践指导：房颤患者应用非维生素K拮抗剂口服抗凝药
下载请点击：
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1057558, encodeId=a233105e558cd, content=不错 谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Mon Oct 04 14:22:50 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954660, encodeId=c77a95466014, content=资料好好，但无法分享，遗憾！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 14:27:24 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908161, encodeId=738690816176, content=学习 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf645444609, createdName=紫依, createdTime=Tue Dec 15 11:33:44 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300310, encodeId=27e0300310f9, content=谢谢分享.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/13/c36860368f59b7f042bac242c6785040.jpg, createdBy=457b1858657, createdName=ms2296823935859672, createdTime=Tue Mar 27 22:52:43 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300300, encodeId=38b03003000f, content=不错的文章值得推荐, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Tue Mar 27 22:38:49 CST 2018, time=2018-03-27, status=1, ipAttribution=)]
    2021-10-04 H8888888

    不错 谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1057558, encodeId=a233105e558cd, content=不错 谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Mon Oct 04 14:22:50 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954660, encodeId=c77a95466014, content=资料好好，但无法分享，遗憾！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 14:27:24 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908161, encodeId=738690816176, content=学习 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf645444609, createdName=紫依, createdTime=Tue Dec 15 11:33:44 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300310, encodeId=27e0300310f9, content=谢谢分享.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/13/c36860368f59b7f042bac242c6785040.jpg, createdBy=457b1858657, createdName=ms2296823935859672, createdTime=Tue Mar 27 22:52:43 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300300, encodeId=38b03003000f, content=不错的文章值得推荐, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Tue Mar 27 22:38:49 CST 2018, time=2018-03-27, status=1, ipAttribution=)]
    2021-04-07 ms6000001015893838

    资料好好，但无法分享，遗憾！

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1057558, encodeId=a233105e558cd, content=不错 谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Mon Oct 04 14:22:50 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954660, encodeId=c77a95466014, content=资料好好，但无法分享，遗憾！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 14:27:24 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908161, encodeId=738690816176, content=学习 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf645444609, createdName=紫依, createdTime=Tue Dec 15 11:33:44 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300310, encodeId=27e0300310f9, content=谢谢分享.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/13/c36860368f59b7f042bac242c6785040.jpg, createdBy=457b1858657, createdName=ms2296823935859672, createdTime=Tue Mar 27 22:52:43 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300300, encodeId=38b03003000f, content=不错的文章值得推荐, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Tue Mar 27 22:38:49 CST 2018, time=2018-03-27, status=1, ipAttribution=)]
    2020-12-15 紫依

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1057558, encodeId=a233105e558cd, content=不错 谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Mon Oct 04 14:22:50 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954660, encodeId=c77a95466014, content=资料好好，但无法分享，遗憾！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 14:27:24 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908161, encodeId=738690816176, content=学习 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf645444609, createdName=紫依, createdTime=Tue Dec 15 11:33:44 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300310, encodeId=27e0300310f9, content=谢谢分享.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/13/c36860368f59b7f042bac242c6785040.jpg, createdBy=457b1858657, createdName=ms2296823935859672, createdTime=Tue Mar 27 22:52:43 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300300, encodeId=38b03003000f, content=不错的文章值得推荐, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Tue Mar 27 22:38:49 CST 2018, time=2018-03-27, status=1, ipAttribution=)]
    2018-03-27 ms2296823935859672

    谢谢分享.学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1057558, encodeId=a233105e558cd, content=不错 谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Mon Oct 04 14:22:50 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954660, encodeId=c77a95466014, content=资料好好，但无法分享，遗憾！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 14:27:24 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908161, encodeId=738690816176, content=学习 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf645444609, createdName=紫依, createdTime=Tue Dec 15 11:33:44 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300310, encodeId=27e0300310f9, content=谢谢分享.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/13/c36860368f59b7f042bac242c6785040.jpg, createdBy=457b1858657, createdName=ms2296823935859672, createdTime=Tue Mar 27 22:52:43 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300300, encodeId=38b03003000f, content=不错的文章值得推荐, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Tue Mar 27 22:38:49 CST 2018, time=2018-03-27, status=1, ipAttribution=)]
    2018-03-27 131****2916

    不错的文章值得推荐

    0

相关指南

2017 EHRA/ESC共识文件：心脏瓣膜病相关性房颤的抗栓治疗

欧洲心律学会(EHRA,European Heart Rhythm Association) · 2017-11-01

2017 AAFP临床实践指南：新发现房颤的药物治疗（更新版）

美国家庭医师学会(AAFP,American Academy of Family Physicians) · 2017-04-01

2017 HRS/EHRA/ECAS/APHRS/SOLAECE专家共识声明：房颤导管和外科消融

欧洲心律学会(EHRA,European Heart Rhythm Association) · 2017-05-12

2017 AATS专家共识指南：房颤外科消融治疗

美国胸外科协会(AATS,American Association for Thoracic Surgery) · 2017-04-12

【专题】最新观点更新与解读，知识的扩容--房颤指南荟萃

暂未更新 · 2017-03-31

2017年STS房颤外科消融治疗指南的解读

暂未更新 · 2016-12-31